The use of atherosclerotic cardiovascular disease (ASCVD) risk to personalize systolic blood pressure (SBP) treatment goals is a topic of increasing interest. Therefore, we studied whether coronary artery calcium (CAC) can further guide the allocation of anti-hypertensive treatment intensity.
E levated blood pressure (BP) is a major cause of heart disease, stroke, and heart failure, with more than 972 million adults worldwide and approximately 1 in 3 US adults diagnosed with hypertension. 1 Although effective antihypertensive pharmacotherapies are widely available, 2 controversy regarding the optimal systolic BP (SBP) threshold to initiate or intensify treatment has increased recently. For example, relying on data from randomized trials (and excluding observational results), a 2014 report by the eighth panel appointed to the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure found no trial evidence to support initiating therapy until an SBP of ≥150 mm Hg in adults ˃60 years of age who do not have diabetes mellitus or chronic kidney disease. 3 This recommendation was controversial 4 and differs from other guidelines and advisories, the majority of which recommend a lower threshold of 140 mm Hg.
Furthermore, after these Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure recommendations were released, the landmark Systolic Blood Pressure Intervention Trial (SPRINT) 5 reported significant improvements in outcomes, notably atherosclerotic cardiovascular disease (ASCVD) and heart failure, among 9361 high-risk nondiabetic hypertensive patients, ˃50 years of age treated to a SBP target of ≤120 mm Hg versus the standard target of ≤140 mm Hg. Thus, questions remain about whom to treat and with what treatment intensity, particularly among individuals with prehypertension or mild hypertension.
In this context, interest has heightened in the use of global ASCVD risk estimates-in conjunction with SBPto guide initiation and titration treatment decisions for hypertension. [6] [7] [8] [9] This strategy may allow providers to balance the tension between avoiding overtreatment among low-risk persons who are unlikely to benefit and intensifying treatment to achieve lower SBP in higher risk adults. Earlier reports of risk-based allocation of BP therapy have focused exclusively on risk estimates derived from traditional clinical risk factors such as those included in the American College of Cardiology/American Heart Assocation 2013 ASCVD risk score. 6, 8, 10, 11 Coronary artery calcium (CAC), measured by noncontrast cardiac computerized tomography (CT), is a powerful subclinical marker of absolute and relative ASCVD risk, and it has been demonstrated to add incremental prognostic information to risk estimates derived from traditional risk factors. [12] [13] [14] In addition, previous analyses have suggested that CAC testing has the potential to personalize allocation of other preventive therapies (eg, aspirin or statin) by identifying individuals who are unlikely to obtain net benefit (eg, those with CAC=0 generally have low absolute 10-year risk and, hence, high estimated number-needed-totreat [NNT]), as well as those who may be more likely to benefit because of high absolute risk (eg, CAC >100). 15, 16 Therefore, in this study, we sought to determine whether CAC might inform the identification of primary prevention candidates who are more likely to benefit from initiation or titration of antihypertensive therapy to a more intensive SBP goal of 120 mm Hg (compared with the current standard of 140 mm Hg).
METHODS Study Participants
Multi-Ethnic Study of Atherosclerosis (MESA) is a multicenter, multi-ethnic, prospective observational cohort study. 17 Between July 2000 and August 2002, MESA recruited 6814 men and women 45 to 84 years of age from four ethnic groups (white, black, Chinese American, and Hispanic). Participants were enrolled from 6 geographically distinct US communities. Exclusion criteria included clinical CVD at baseline. All participants provided informed consent, and the study was approved by the institutional review boards at all field centers.
Clinical Perspective
What Is New?
• A given magnitude of blood pressure lowering provides similar relative benefit at all levels of cardiovascular disease risk but progressively greater absolute benefit (and therefore a lower number needed to treat) as risk increases, suggesting that persons at high risk are more likely to derive net benefit from more intensive blood pressure goals (eg, systolic ≤120 mm Hg as supported by the Systolic Blood Pressure Intervention trial [SPRINT]). • To our knowledge, this study is the first to incorporate information on individual coronary artery calcium (CAC) burden to personalize the risk-based treatment of hypertension.
• Added to both traditional risk factor-based estimation of cardiovascular disease risk and a discussion of patient treatment preferences, CAC can help identify individuals who may benefit from more intensive treatment to a systolic blood pressure goal of ≤120 mm Hg versus a more traditional goal of ≤140 mm Hg.
What Are the Clinical Implications?
• Information on CAC burden (particularly when CAC results have already been obtained for other reasons) may be considered when making personalized treatment decisions about blood pressure targets, particularly among persons with an estimated cardiovascular disease risk between 5% and 15% and who have either prehypertension or mild hypertension.
• A precision medicine clinical trial evaluating riskbased blood pressure treatment goals, preferably incorporating CAC and not just risk factor-based estimations, is now needed.
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The primary sample for this analysis excluded MESA participants with baseline systolic BP levels ˂120 mm Hg (n=2939) and ≥180 mm Hg (n=136). We excluded persons with SBP <120 mm Hg a priori because we determined that CAC screening among these adults for the purposes of BP management would be inappropriate because treating adults with SBP <120 to even lower BPs (irrespective of CAC) is difficult to justify. We also excluded those with SBP ≥180 mm Hg because (1) this was an outlier SBP phenotype in the sample (just 1.9%); (2) SBP at this level is consistent with hypertensive urgency, is high risk, and requires rapid therapy not CAC testing to target specific goals; and (3) we did not want to include individuals with possible secondary hypertension in the analysis. In addition, we excluded 6 persons with missing information on baseline SBP or BP medication use, leaving 3733 participants in total. We also conducted secondary analyses using a subsample of MESA participants who fulfilled SPRINT criteria. 5 This subsample included only patients without diabetes mellitus who were ˃50 years of age with systolic BP ≥130 mm Hg and had any 1 of the following; Framingham CVD 10-year risk ≥15%, left ventricular hypertrophy by electrocardiogram or ankle-brachial index <0.9, or estimated glomerular filtration rate between 20 and 59 mL/ min/1.73 m 2 . After exclusions, this subsample included 1394 participants.
CV Risk Factors
Race, family history of myocardial infarction, and smoking status were collected by self-report. Body mass index was calculated as weight in kilograms divided by height in meters squared. Diabetes mellitus was defined as a fasting blood glucose concentration of ≥126 mg/dL, self-report, or the use of insulin or oral hypoglycemic medications. Seated BP was recorded after a minimum of 5 minutes rest as the mean of the last 2 of 3 seated measurements using a Dinamap Pro-100 automated oscillometric sphygmomanometer. 18 Participants were asked to bring their medications to the clinic, and antihypertensive and statin drug use was assessed with a medication inventory. Total cholesterol, high-density lipoprotein cholesterol, and triglyceride measurements were performed in blood samples obtained after a 12-hour fast. Low-density lipoprotein cholesterol was calculated using the Friedewald equation. The 10-year risk of hard ASCVD events for MESA participants was estimated using the American College of Cardiology/American Heart Assocation Pooled Cohort Equations (with Hispanics/Chinese calculated as white). 10 
Cardiac CT Protocol
The MESA scanning protocol has been published. 19 Cardiac CT was performed at baseline at 3 MESA sites using a cardiac-gated electron-beam CT scanner (Imatron C-150XL, GE-Imatron) and at 3 sites using a 64-slice multidetector CT scanner. Both scanner types produce near identical results. 19 Intra-and interobserver agreements were excellent (κ = 0.93 and κ = 0.90, respectively). Although no action was required based on CAC results, participants were told that they had no CAC or that the amount was less than average, average, or greater than average for their age and sex, and to discuss the results with their physicians.
Definition of CV Events
The primary end point of all-cause CVD or hospitalized heart failure was prespecified to match the composite outcome used in SPRINT. 5 Secondary individual end points included all-cause CVD, heart failure, all-cause coronary heart disease (CHD), and stroke. At intervals of 9 to 12 months, an interviewer contacted each subject or a family member about outpatient diagnoses of CHD or CVD, interim hospitalizations, and deaths. Two physicians from the MESA mortality and morbidity review committee independently classified events; in the event of disagreement, the full committee adjudicated. With follow-up through 2012, MESA was successful in obtaining information on 98% of reported hospitalized CVD and 95% of reported outpatient CVD encounters.
All-cause CHD events were defined as myocardial infarction, death from CHD, probable angina resulting in revascularization, or resuscitated cardiac arrest. All-cause CVD events were defined as all-cause CHD events plus cerebrovascular accident (transient ischemic attack or ischemic or hemorrhagic stroke), cerebrovascular accident death, or other CVD death. MESA reviewers classified incident heart failure as definite, probable, or absent. Probable or definite hospitalized heart failure both required symptoms, such as shortness of breath or edema, as baseline criteria. Probable hospitalized heart failure further required heart failure diagnosed by a physician and patient receiving medical treatment for heart failure. To meet criteria for definite hospitalized heart failure, 1 or more additional factors, such as pulmonary edema by X-ray, poor left ventricular systolic function, or diastolic dysfunction, were also required. Participants who suffered both CVD and heart failure were censored from this analysis after the first event. More details of the MESA follow-up methods are available at the MESA website (http://www.mesa-nhlbi.org).
Statistical Analysis
To examine the potential implications of CAC testing for both intensification (eg, titration) and initiation of BP therapy to a more intensive SBP goal, we included persons with and without baseline anti-hypertensive medication use (Table 1) . We calculated proportions for categorical variables and either mean±standard deviation or median±interquartile range for continuous variables with normal and non-normal distributions, respectively. Groups were compared using 2-sample t test, Mann-Whitney, or χ-square testing as appropriate.
In survival analyses, participants were categorized into these systolic BP categories: <140 mm Hg (ie, either 120-139 mm Hg for the MESA study sample or 130-139 mm Hg for the SPRINT-eligible subsample), 140 to 159 mm Hg, and 160 to 179 mm Hg. Then to evaluate whether CAC can personalize risk assessment among subgroups of varying SBP and ASCVD risk estimates, these BP categories were further stratified on the basis of, first, 10-year ASCVD risk (<15% or ≥15%, 5, 6, 20 which was the median level of risk in our primary sample), and, second, CAC group (0, 1-100, >100). We compared crude event (incidence) rates and Cox multivariable-adjusted hazard ratios within each of these CAC strata.
Models were adjusted for age, sex, race, body mass index, fasting glucose, diabetes mellitus status (yes or no), creatinine, smoking category, low-density lipoprotein cholesterol, highdensity lipoprotein cholesterol, triglycerides, statin use, and family history of myocardial infarction (yes or no). In models where the sample was stratified by ASCVD (<15% or ≥15%), we adjusted for core demographics and variables not included in the ASCVD equation (body mass index, creatinine, triglycerides, statin use, and family history of myocardial infarction). We conducted sensitivity analyses with more parsimonious models adjusted just for demographics alone (age, sex, and race). Using the 13 variables included in the primary model, we also constructed a propensity score for the composite outcome within each of the CAC subgroups and adjusted the model for this score as a single variable.
We estimated a 10-year number needed to treat to prevent the primary outcome of all-cause CVD or heart failure (10-year NNT [NNT 10 ]) with treatment initiation or intensification to a SBP goal of 120 mm Hg. This number was calculated by applying the expected relative risk reduction derived either from metaanalysis (22% reduction in CHD, 41% reduction in stroke, and 24% reduction in heart failure for each 10 mm Hg lowering of SBP 21 ) in the primary sample or directly from SPRINT (25% relative reduction for a target of 120 mm Hg versus a target of 140 mm Hg 5 ) in the secondary analysis of the SPRINT-eligible subsample. The NNT 10 was calculated directly as the reciprocal of the absolute risk difference at the median follow-up of the cohort on the basis of Kaplan-Meier estimates and was subsequently adjusted to an NNT 10 according to the Altman-Anderson method. 22 In a sensitivity analysis, using the same statistical techniques, we modeled NNT 10 for an SBP goal of 130 mm Hg. We also conducted a sensitivity analysis of NNT 10 for a goal (24) 349 (20) 139 (23) 146 (19) Chinese 238 (12) 172 (10) 73 (12) 77 (10 Values are for number (%), median (interquartile range), or mean (±SD). *P-values are for differences between groups using 2-sample t test, Mann-Whitney, or χ2 as appropriate. ASCVD indicates atherosclerotic cardiovascular disease; BP, blood pressure; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoproteincholesterol; MESA, Multi-Ethnic Study of Atherosclerosis; MI, myocardial infarction; and SPRINT, Systolic Blood Pressure Intervention Trial.
of 120 mm Hg using risk categorization that included lower cut points of 10-year estimated ASCVD risk (<5% or <10%). Finally, we estimated NNT 10 for an SBP goal of 120 mm Hg to prevent each of the individual end points included in the main composite (CHD, stroke, and heart failure), and we also conducted analyses in the diabetic mellitus subgroup of our primary MESA sample.
RESULTS
Baseline characteristics of the primary sample and the SPRINT-eligible subsample, stratified by anti-hypertensive medication use are shown in Table 1 . Except for a lower proportion of males and being less likely to smoke, persons receiving BP therapy at baseline were older and had a higher burden of ASCVD risk factors than those who were not on BP therapy at baseline. Those receiving BP therapy also had higher SBP than those not on therapy. Diastolic BP levels, although clinically similar (75.6 vs 76.2 mm Hg), were statistically lower among those on BP therapy. The distribution of CAC also differed according to baseline BP treatment status (Figure 1 ).
Over a median (interquartile range) follow-up of 10.2 (9.7-10.7) years, 642 primary composite outcome events (all-cause CVD or heart failure) occurred in the sample overall. Figure 2 demonstrates that cumulative event-free survival was significantly lower, in both the primary sample and SPRINT-eligible subsample, among individuals with CAC 1 to 100 and >100, compared with those with CAC=0. Similar trends were demonstrated after stratification by baseline SBP category (onlineonly Data Supplement Figure I ). These trends were also qualitatively similar for the individual outcomes of CHD, stroke, and heart failure (online-only Data Supplement Figure II ).
Among persons in the primary sample who were not on baseline BP therapy, event rates were low for those with CAC=0 and SBP between 120 and 139 mm Hg (5.6 per 1000 person-years) or between 140 and 159 mm Hg (7.4 per 1000 person-years). However, event rates ap- *P value by log-rank testing.
peared to be high, irrespective of CAC level, in persons with untreated SBP between 160 and 179 mm Hg (ranging from ≈20-40 per 1000 person-years; Table 2 ). In general, event rates were also consistently higher among those on baseline BP therapy compared with untreated individuals within each of the BP and CAC strata. Of note, however, persons not on BP therapy with SBP between 120 and 139 mm Hg and CAC >100 had a similar event rate (24.3 per 1000 person-years) as individuals on therapy with both poorly controlled hypertension (SBP 160-179 mm Hg) and CAC=0 (20.2 per 1000 person-years). Adjusted Cox models confirmed that, relative to CAC=0, CAC 1 to 100 and CAC >100 carried incremental excess in hazard for events among persons with SBP in the 120 to 139 mm Hg and 140 to 159 mm Hg ranges irrespective of baseline treatment status (Table 2) . However, associations between CAC and hazard for events among those with SBP 160 to 179 mm Hg were not statistically significant, either with or without baseline therapy. All of these trends were qualitatively similar in the SPRINT-eligible subsample. Table 3 demonstrates findings after individuals within each SBP category, both untreated and treated combined, were stratified by estimated 10-year ASCVD risk (above or below the sample median of 15%). Those with CAC=0 had low event rates in both the 120 to 139 mm Hg (4.6 per 1,000 person-years) and 140 to 159 mm Hg BP categories (6.9 per 1000 person-years) as long as ASCVD risk was <15%. Event rates were comparably higher (>7.5 per 1000 person-years) in all persons with SBP between 160 and 179 mm Hg. Furthermore, persons with baseline ASCVD risk ≥15% at all levels of baseline SBP also had higher event rates, again irrespective of CAC level (ranging from ≈13-46 per 1000 person-years).
Adjusted Cox models demonstrated increased hazard for events with CAC 1 to 100 and CAC >100 (vs CAC=0) among those who had SBP levels in the range of 120 to 139 mm Hg and 140 to 159 mm Hg but no statistical association of CAC with CVD among those with SBP 160 to 179 mm Hg (Table 3) . Excess relative hazard with increasing CAC strata was most pronounced in those with estimated ASCVD risk <15%. Parsimonious demographic-adjusted and propensity score-adjusted models produced similar results (online-only Data Supplement Tables I through IV). As in Table 2 , all of these trends were qualitatively similar in the SPRINT-eligible subsample. None of the hazard ratios presented in Table 3 demonstrated any interaction by race.
The absolute differences in event rates according to baseline CAC translated into substantial variation in estimated NNT 10 to prevent all-cause CVD or heart failure with BP lowering to a SBP goal of 120 mm Hg. For example, a low NNT 10 (between 4 and 8), was estimated for persons with CAC >100 in both the SBP 140 to 159 mm Hg and 160 to 179 mm Hg categories irrespective of baseline estimated ASCVD risk (Table 4 ). In contrast, participants with CAC=0 had higher estimated NNT 10 at all levels of baseline SBP and ASCVD risk. Persons with SBP <140 mm Hg, ASCVD risk <15% and CAC=0 had the highest NNT 10 estimates (NNT 10 =99). Likely because of the higher baseline SBP and ASCVD risk in those who were SPRINT eligible, with higher consequent event rates, all NNT 10 levels were relatively low in this subsample. The NNT 10 results were qualitatively similar when the sample overall was stratified by baseline treatment status (as such, NNT 10 for a goal SBP of 120 mm Hg was similar for both initiation of BP therapy and intensification of prior therapy; online-only Data Supplement Table V) . Because CAC stratifies absolute risk for CHD, stroke, and heart failure, the NNT 10 trends seen for the composite outcome are mirrored in each of the individual outcomes (online-only Data Supplement Table VI) . Figure 3 summarizes the range of NNT 10 estimates after stratification by baseline CAC, with findings most widely dispersed among those with ASCVD risk <15% and who had either prehypertension or mild hypertension. In addition, sensitivity analyses evaluating lower ASCVD risk cut points suggested that, among participants with SBP 120 to 139 mm Hg, 32% of persons with ASCVD risk <7.5% had CAC>0 (with NNT 10 estimates for a 120 mm Hg SBP goal of 76 for CAC1-100 and 47 for CAC>100), whereas CAC>0 was less frequent and NNT 10 estimates were *NNT for the MESA sample is calculated as follows: for each SBP category, we took the mean SBP in this category and subtracted 120 to get the target BP reduction (eg, if mean is 130 mm Hg in the SBP <140 mm Hg category, then to achieve 120 mm Hg, the target reduction would be 10 mm Hg). For each 10 mm Hg reduction, we estimate a 22% reduction in CHD, 41% reduction in stroke, and 24% reduction in HF.
†NNT for the SPRINT subsample assumes a 25% relative reduction in the main outcome. ‡ <140 SBP is 120-139 mm Hg for primary sample and 130-139 mm Hg for SPRINT subsample. ASCVD indicates atherosclerotic cardiovascular disease; BP, blood pressure; CAC, coronary artery calcium; CI, confidence interval; MESA, Multi-Ethnic Study of Atherosclerosis; NNT, number needed to treat; SBP, systolic BP; and SPRINT, Systolic Blood Pressure Intervention Trial.
higher among those with ASCVD risk <5% (eg, NNT 10 estimates for a 120 mm Hg SBP goal of 180 for the 20% with CAC 1-100 and 37 for the 3% with CAC>100) (online-only Data Supplement Table VII) .
The exploratory analysis of diabetics in our sample suggested that NNT 10 estimates were low, irrespective of CAC, among those with 10-year ASCVD risk ≥15%. Too few diabetics in our sample had ASCVD risk <15% to judge whether CAC has any role in guiding risk-based BP therapy in this setting (online-only Data Supplement Table VIII ). Finally, online-only Data Supplement Table IX demonstrates our NNT 10 estimates from the sensitivity analysis evaluating an SBP goal of 130 mm Hg. As expected, NNT 10 estimates were higher (ie, less benefit) when targeting 130 mm Hg compared with 120 mm Hg systolic, particularly among those at highest risk as reflected by elevated baseline CAC.
DISCUSSION
Our results add to an emerging body of literature suggesting that ASCVD risk may be useful in defining more personalized BP goals and could guide a precision medicine approach for both initiation and intensification of antihypertensive treatment. First, CAC was a powerful determinant of absolute risk for the composite of all-cause CVD or heart failure. Second, persons with CAC=0 in both the prehypertension (120-139 mm Hg) and mild hypertension (140-159 mm Hg) SBP categories had low 10-year event rates (eg, <7.5 per 1000 person-years). This finding was particularly true for those not already on BP therapy at baseline, in whom the decision to initiate treatment may be under consideration, but also applied to persons on baseline therapy in whom intensification of treatment may be considered. All participants with SBP >160 mm Hg had high event rates irrespective of CAC levels.
Third, CAC may be most suitable for guiding therapeutic decisions (specifically, either initiation or intensification to a more intensive systolic goal of 120 mm Hg) when both SBP is between 120 and 159 mm Hg and 10-year ASCVD has been estimated as <15%. In these individuals, CAC=0 yielded a higher estimated NNT for persons with SBP 140 to 159 mm Hg (NNT 10 = 36) and, above all, for those with SBP between 120 and 139 mm Hg (NNT 10 = 99), suggesting lower likelihood for benefit. The latter group consists of those in whom the decision to treat to a more intensive goal of 120 mm Hg (compared with the traditional goal of 140 mm Hg) may be most challenging in the context of results from SPRINT. Given that 97% of MESA participants with estimated ASCVD risk <5% have CAC <100 and NNT 10 estimates ranging from 180 to 273, our sensitivity analyses suggest that CAC may be most practical for this purpose when SBP is between 120 and 159 mm Hg and estimated ASCVD risk is between 5% and 15%.
These inferences are most appropriately applied to general community intermediate-to low-risk populations similar to MESA. Our secondary analysis results suggest The number-needed-to-treat (NNT) estimates within each category of ASCVD risk (calculated using traditional risk factors according to the 2013 ACC/AHA pooled cohort equations 14 ) and SBP consist of mean 10-year NNT (NNT 10 ) for persons with CAC=0 (upper limit), mean NNT 10 for persons with CAC 1 to 100 (solid square), and mean NNT 10 for persons with CAC >100 (lower limit)
that the relatively few adults fulfilling strict SPRINT eligibility criteria (just 7.6% of the overall US population 23 ) are, by definition, at high risk for CVD or heart failure, and the further use of CAC imaging in these individuals may be less helpful in deciding SBP goals.
The traditional paradigm of allocating BP therapy solely on BP values makes intuitive and physiological sense. However, data have consistently demonstrated that, although the relative risk reduction in events per unit of SBP lowering is the same, the absolute risk reduction, NNT and, hence, clinical efficacy of BP treatment increases as baseline absolute ASCVD risk increases. 8 In fact, the idea of using baseline ASCVD risk to guide BP therapy is not new. 24, 25 Moreover, the concept of using risk to allocate ASCVD prevention therapies has taken center stage after the release of 2013 American College of Cardiology/American Heart Assocation guidelines for the treatment of cholesterol in adults, which recommend statins be considered based on an ASCVD risk of ≥7.5% and not solely on low-density lipoprotein cholesterol values. 26 Indeed, recent data from the Heart Outcomes Prevention Evaluation trial (HOPE)-3 support the concept of risk-based allocation of BP therapy. In this study, 12 705 intermediate-risk adults with baseline SBP of 138 mm Hg were randomized to placebo or to a combination of 12.5 mg hydrochlorothiazide and 16 mg candesartan. Despite a relative SBP reduction of 6 mm Hg (which was notably less than the 14.8 mm Hg achieved in SPRINT), the intermediate-risk adults enrolled in HOPE-3 did not derive benefit. 27 Thus, SPRINT supports intensive BP control (SBP goal of 120 mm Hg) in high-risk patients, whereas HOPE-3 suggested that intermediate-risk patients may be suitable for less stringent SBP goals. However, our findings introduce the potential value of CAC testing in this intermediate-risk group to reclassify individual risk and inform more personalized intensive SBP goals in those with advanced subclinical atherosclerosis.
Presumably BP values will always be important in allocating antihypertensive therapy, and our data support this. Specifically, participants in our analysis with SBP >160 mm Hg had high event rates and low NNT irrespective of baseline ASCVD risk or CAC. With the exception of those with ASCVD risk <15% and CAC=0, this was also true for persons with BP 140 to 159 mm Hg. Nonetheless, adding ASCVD risk into BP treatment decisions could potentially allow consideration of therapy for a large number of persons with SBP levels that, before SPRINT, were otherwise not typically considered to benefit from treatment initiation or intensification (eg, those with SBP 120-139 mm Hg). 6 For example, Karmali et al 11 found that most excess ASCVD events occur in persons with BP levels considered at goal by the 8th Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure and that the vast majority of those who suffer these events have elevated ASCVD risk.
Estimating risk based on traditional risk factors alone can be misleading, 28 and CAC has been repeatedly shown to improve the accuracy of risk assessment. 29, 30 Furthermore, we have previously shown that CAC may inform NNT estimation for other ASCVD prevention therapies. 15, 16 In addition, CAC and intensive BP control such as that used in SPRINT both have supportive evidence for cost-effectiveness. 31, 32 As such, our data could extend the utility of CAC to guiding riskbased determination of more personalized systolic BP goals in persons with mild hypertension and prehypertension. This may be relevant for deciding whether to refer for CAC imaging but is particularly meaningful for those who have already had CAC testing for other reasons.
It is important to note that our analyses incorporate clinically relevant information on both baseline BP and estimated ASCVD risk into the calculation of CAC-based NNT estimates. This approach is crucial because we believe that CAC should not be used in isolation in this context. Specifically, as long as ASCVD risk is <15% and SBP is between 120 and 159 mm Hg, our results suggest the potential for CAC=0 to allow more liberal BP treatment goals (eg, 140 mm Hg), particularly if based on individual patient preferences. 33 Indeed, CAC may be most helpful in cases where physicians are considering intensifying treatment to a SPRINT-based SBP goal of <120 mm Hg among persons with SBP between 120 and 139 mm Hg (ie, levels below the current traditional goal of 140 mm Hg). In this setting, when ASCVD risk is <15%, a CAC=0 yields an NNT 10 of ≈100, information that could guide the clinical-patient treatment discussion. Given the low burden of CAC and events among those with ASCVD estimates <5%, CAC imaging to guide personalized SBP goals may be best suited to persons with estimated ASCVD risk 5% to 15%.
Although we found that CAC-based NNT 10 estimates were generally higher for a target of 130 mm Hg (vs 120 mm Hg), the overall message was the same: NNT 10 estimates for the prevention of ASCVD or heart failure suggest that lower systolic targets (eg, either 120 or 130 mm Hg) may be superior to the traditional target of 140 mm Hg when: (1) SBP is >160 mm Hg, (2) estimated CVD risk using traditional risk factors is >15%, and, most important, (3) CAC>100 among those individuals currently in the therapeutic "grey zone" (ie, those with SBP in the prehypertension and mild hypertension range and who are at intermediate risk by CVD risk scores).
Our analysis has some limitations. Although we believe that our findings may have important clinical implications and can guide future investigation, they are hypothesis-generating because of the observational nature of the data and the limited numbers of events among certain subgroups. The latter consideration is most relevant among those with SBP 160 to 179 mm Hg and for our SPRINT-eligible subsample. Our NNT estimates are based on a number of assumptions (in particular that the relative risk reduction for BP therapy is similar among CAC strata). Nonetheless, we feel they are informative. Although some have argued that SPRINT SBP values cannot easily be translated into routine care, 34 we note that the MESA BP measurement protocol was nearly identical to SPRINT and that MESA also used automated oscillometric BP measurement devices. Because MESA was not designed to capture accurate time-to-event data on side effects of anti-hypertensive medication (eg, electrolyte imbalance or injurious falls), we do not have absolute event rates for these outcomes among CAC strata, and we are unable to generate number-needed-to-harm estimates. For simplicity, we did not incorporate information on diastolic BP because the optimal goal for this parameter (80-89 mm Hg) is more widely agreed on, because diastolic BP does not typically add to ASCVD risk estimation over and above SBP, and because so few MESA participants had isolated diastolic hypertension (n=40, 0.6%).
CONCLUSION
Assessment of CAC may inform more personalized BP goals (eg, choosing between a traditional SBP goal of 140 mm Hg or a more intensive goal of 120 mm Hg), particularly among persons with baseline 10-year AS-CVD risk estimates between 5% and 15% and who have systolic BP levels between 120 and 159 mm Hg. Specifically, among these individuals, CAC >100 appears to identify those who would likely benefit from an intensive SBP goal of 120 mm Hg, whereas CAC=0 identifies individuals who may be suitable for more traditional SBP goals, thereby avoiding unnecessary intensification of medication and instead focusing on healthy lifestyle measures. A trial of risk-based allocation of BP treatment goals, preferably incorporating CAC, is needed.
